Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sionna Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, specifically targeting the NBD1 domain. The company reports significant operating losses and anticipates needing substantial additional funding to advance its lead dual combination candidate, SION-451 + SION-2222, through clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-32.4-20.3
EPS (diluted, $ a share)$-0.72$-0.46

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SION. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sionna Therapeutics, Inc.: key numbers

Share price
$3.12Close, Nov 16
Market cap
$141M
Shares outstanding
45.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sionna Therapeutics, Inc.

All →
7:06 AM ET 8-K
Financial Results

Sionna Therapeutics Financial Results

Sionna Therapeutics reported Q3 2026 financial results and announced plans to initiate the AscenSION CF Phase 2 proof-of-concept trial for its SION-451 and SION-2222 dual combination in Q1 2027. The company ended the quarter with $249.8 million in cash, which is expected to fund operations into the second half of 2029.

Term
Q3 2026

“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination. We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”

Mike Cloonan, President and Chief Executive Officer
6:57 PM ET Form 4
Insider Selling

Sionna Therapeutics Director Ra Capital Management L.P. Sells $21.8M of Stock

Ra Capital Management L.P., Director, sold 3,448,811 shares of Sionna Therapeutics, Inc. at $6.32 to $7.46 a share (average $6.33) in 2 transactions, worth $21.8M in total on Sep 17, 2026. Shares held after the trade: 3,448,812 (-1.0%).

Value
$21.8M
Shares
3,448,811
Average price
$6.33
Role
Director
Holding change
-1.0%
Trade date
Sep 17, 2026
4:11 PM ET 8-K
Other 8-K Filing

Sionna Therapeutics Other 8-K Filing

Sionna Therapeutics approved a restructuring plan to focus resources on its SION-451 and SION-2222 dual combination program, involving a 46% workforce reduction and the wind-down of its SION-719 add-on program. The company expects to incur approximately $6.4 million in restructuring charges, primarily for severance and contract close-out costs, while extending its cash runway into the second half of 2029. Additionally, Chief Business Officer Caroline Stark Beer was terminated without cause as part of the reorganization.

Earnings call
Sep 14, 2026, 4:30 PM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.